arcoris bio Raises Funds for Breakthrough Technology
In a significant step towards advancing biomarker technology, arcoris bio has successfully raised CHF 6.3 million in a seed funding round. This financing is crucial for bolstering the development and commercialization of the company’s innovative MUSE® platform, which is designed to elevate the capabilities of digital pathology.
Leadership and Investor Confidence
The seed round was co-led by renowned investors Ventura Ace and ZEISS Ventures, alongside participation from Zürcher Kantonalbank (ZKB) and both new and existing private investors. This robust investor support serves as a validation of arcoris bio's technical expertise and strategic vision.
Comments from Leadership
Simon Restrepo, Co-founder and Chief Scientific Officer, expressed his enthusiasm regarding the backing from industry leaders. "Attracting investors with profound industry knowledge strengthens our technical and business strategy. Their support drives our mission of transforming biomarker detection and enhancing digital pathology," he stated.
Funding Impact on Product Development
The influx of funds will accelerate the industrialization of the MUSE® platform, foster strategic partnerships, and initiate the launch of new products. Matyas Vegh, the CEO, emphasized the milestone this funding represents for arcoris bio. "In a challenging market, we appreciate the trust our investors grant us, enabling us to expedite bringing our innovations to market and expanding our operational capabilities," he noted.
The MUSE® Advantage
The MUSE® platform empowers researchers by facilitating the simultaneous detection of multiple biomarkers with high sensitivity and ease. This innovative technology can measure multiple difficult-to-detect biomarkers in a single sample, leading to increased throughput and effectiveness in digital pathology applications.
Industry Validation and Future Potential
Both investors expressed strong confidence in the potential of arcoris bio's technology. Andreas Jenne, Investment Director at Ventura Ace, highlighted the team's vision and traction with industry partners as compelling reasons for their investment. Jenne remarked, "MUSE® could become a fundamental technology in the realm of digital pathology, enabling a variety of diagnostic applications that can improve patient outcomes."
The Future of Diagnostics
Benedikt Klaes, Senior Investment Manager at ZEISS Ventures, articulated the crucial gap that MUSE® fills in diagnostics. "This technology not only aids in better diagnostics but also enhances applications such as drug discovery and precision medicine. Its versatility and universal applicability add to its significance in the market," Klaes elaborated.
About arcoris bio
arcoris bio is dedicated to developing state-of-the-art biomarker detection technologies for research and diagnostic purposes. Its flagship MUSE® platform utilizes groundbreaking signal amplification techniques to allow for highly sensitive and multiplex assays, paving the way for advancements in digital pathology. Founded by industry innovators including Simon Restrepo and Scott E. Fraser, alongside entrepreneur H. Kaspar Binz, arcoris bio is based in Schlieren, Switzerland.
Frequently Asked Questions
What is arcoris bio's primary focus?
arcoris bio specializes in next-generation technologies for biomarker detection, primarily aimed at research and diagnostics.
How much funding has arcoris bio raised?
arcoris bio has secured CHF 6.3 million in a seed funding round.
Who are the investors in this funding round?
The funding round was co-led by Ventura Ace and ZEISS Ventures, with additional participation from Zürcher Kantonalbank and new and existing private investors.
What is the MUSE® platform?
The MUSE® platform is arcoris bio's biomarker detection technology that enables the simultaneous detection of multiple biomarkers with high sensitivity.
Where is arcoris bio located?
arcoris bio is headquartered in Schlieren, Switzerland.
